Back to search results

Phase II Study of CRS/HIPEC for Gastric Cancer

This study is testing a treatment called Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for people with gastric adenocarcinoma (stomach cancer). CRS/HIPEC involves surgery to remove all visible tumors, followed by heated chemotherapy directly in the abdomen to target any remaining cancer cells. The study aims to see if this treatment improves how long patients live. You may be able to join if you are 18 or older, have stomach or gastroesophageal junction adenocarcinoma, and meet certain health requirements for your kidneys and bone marrow. The study is currently recruiting 30 participants.

Study design
This is a Phase II interventional study with a planned enrollment of 30 participants. It is analyzing the role of preoperative chemotherapy, preoperative laparoscopic HIPEC, and gastrectomy with CRS/HIPEC.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for survival from enrollment up to 60 months (5 years).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07178808

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

Recruiting
PHASE2Ages 18+InterventionalTreatment
Banner Health
~30 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess improvements in survival in gastric adenocarcinoma patients with occult or apparent carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Measured over From enrollment up to 60 months

Conditions

Gastric Adenocarcinoma

Explore related trials

Gastric Carcinoma

Where it's being run

1 sites across 1 states
Arizona1

Who to contact

James Schohn
[email protected]
480-256-3310
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

1\) Age 18 years and above. There will be no upper age restriction. 2)ECOG performance status ≤ 2. (See Appendix A -ECOG Performance Status Scale). 3)Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction.

Exclusion

1)Distant metastatic disease not limited to peritoneum:

What this trial measures

  • To assess improvements in survival in gastric adenocarcinoma patients with occult or apparent carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapyFrom enrollment up to 60 months

    To determine if preoperative laparoscopic HIPEC and chemotherapy followed by cytoreductive surgery (CRS), gastrectomy and HIPEC in patients with peritoneal surface-only metastasis will improve PFS and/or OS from date of diagnosis of metastatic gastric adenocarcinoma